Shares of Seres Therapeutics Inc (NASDAQ:MCRB) have received an average recommendation of “Buy” from the eight brokerages that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $6.00.
A number of brokerages recently commented on MCRB. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Seres Therapeutics in a research note on Monday. BidaskClub upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, March 6th. Finally, ValuEngine lowered shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, March 9th.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Windsor Creek Advisors LLC acquired a new position in shares of Seres Therapeutics during the 4th quarter worth approximately $35,000. KBC Group NV grew its position in shares of Seres Therapeutics by 7,603.7% during the 4th quarter. KBC Group NV now owns 10,400 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 10,265 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Seres Therapeutics during the 4th quarter worth approximately $39,000. Tower Research Capital LLC TRC acquired a new position in shares of Seres Therapeutics during the 4th quarter worth approximately $42,000. Finally, Citigroup Inc. grew its position in shares of Seres Therapeutics by 191.0% during the 4th quarter. Citigroup Inc. now owns 13,742 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 9,020 shares in the last quarter. Institutional investors and hedge funds own 92.78% of the company’s stock.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.25) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.03. The company had revenue of $7.62 million during the quarter, compared to analyst estimates of $6.82 million. Research analysts forecast that Seres Therapeutics will post -1.01 earnings per share for the current fiscal year.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
Further Reading: Capital Gains Distribution
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.